

**RAINBOW CHILDREN'S MEDICARE LIMITED**

**Corporate Identity Number:** L85110TG1998PLC029914

**Regd. Office:** 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills,  
Hyderabad - 500034, Telangana.

**Corporate Office:** 8-2-19/1/A, Daulet Arcade, Karvy Lane, Road No. 11, Banjara Hills,  
Hyderabad – 500034, Telangana.

**Website:** [www.rainbowhospitals.in](http://www.rainbowhospitals.in); **E-Mail:** [companysecretary@rainbowhospitals.in](mailto:companysecretary@rainbowhospitals.in)

**FAMILIARIZATION PROGRAMME FOR INDEPENDENT DIRECTORS DISCLOSURE UNDER SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

The Familiarization Programme for Independent Directors aims to familiarize them with the Company, their roles, rights, responsibilities in the Company, nature of industry, business model of the Company etc.

The Board of Directors have complete access to the information within the Company. Presentations are made to the Board of Directors/ Audit Committee/ Nomination & Remuneration Committee/ Stakeholders Relationship Committee and Risk Management Committee on various related matters, where Directors get an opportunity to interact with Senior Management. Presentations, inter alia, cover the Company's strategy, business model, operations, markets, organization structure, service offerings, quarterly and annual results, human resources, technology, quality and such other areas as may arise from time to time. With such presentation(s), the new directors, including the Independent Directors, and existing Directors are updated with the Company and its environment.

**Overview of the Familiarization Programme**

**a. Initial familiarization module:**

- (i) The company will furnish its weblink, [www.rainbowhospitals.in](http://www.rainbowhospitals.in). This contains the core information required for the Independent Director in getting familiarized with the company and its operations.
- (ii) The Company will hand over its corporate profile and the Annual Report for the last three years.
- (iii) The company will handover (i) Code of Conduct for Directors & Senior Management Personnel and (ii) Code of Conduct for Prevention of Insider Trading based on SEBI (Prohibition of Insider

Trading) Regulations, 2015 for the Independent Director to understand and comply with the stipulations therein.

The above module shall help the Director to understand the Company, its business and the regulatory framework in which the Company operates and equips him to effectively fulfil his role as a Director of the Company.

**b. For ongoing Familiarization Programme:**

- (i) The company will circulate important communications related to the Company as well as specific regulatory updates by email for advance information in addition to reporting same at the succeeding Board meeting.
  
- (ii) The Board of Directors has complete access to the information within the Company. The Directors are also encouraged to visit various Company's hospitals. Independent Directors have the independence to interact with the Company's management. Independent Directors meet regularly without the presence of any management personnel and their meetings are conducted to enable the Independent Directors to discuss matters pertaining to the Company's affairs and put forth their combined views to the Board of Directors of the Company.

**RAINBOW CHILDREN'S MEDICARE LIMITED**

<b>Details of familiarization programmes attended by the Independent Directors during FY 21-22 (As per Regulation 25 (7) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)</b>							
<b>S. No</b>	<b>Particulars of Programs</b>	<b>No. of Programs Hours</b>	<b>Name of Independent Directors (IDs)</b>				
			<b>Prof. Anil Dhawan</b>	<b>Mr. Aluri Srinivasa Rao</b>	<b>Ms. Sundari. R. Pisupati*</b>	<b>Mr. Santanu Mukherjee**</b>	<b>Mr. Yugandhar Meka#</b>
			<b>No. of Hours attended</b>				
1	Update on initial public offer	3.5	3.5	3.25	2.5	2.66	0.50
2	Business Updates	1.0	1.0	1.0	0.83	0.50	0.66
3	Financial performance, overall business environment and key regulatory developments	1.5	1.5	1.5	1.0	1.0	0.50
4	Board Evaluation - an update on Industry & company practices	0.5	0.5	0.5	0.5	0.5	-
<b>TOTAL</b>		<b>6.5</b>	<b>6.5</b>	<b>6.25</b>	<b>4.83</b>	<b>4.66</b>	<b>1.66</b>
<b>No. of programmes attended by IDs on cumulative basis</b>		<b>4</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>3</b>
<b>No. of hours spent by IDs at programmes on cumulative basis</b>		<b>6.5</b>	<b>6.5</b>	<b>6.25</b>	<b>4.83</b>	<b>4.66</b>	<b>1.66</b>

\* Ms. Sundari R. Pisupati was appointed as an Independent Director on the Board w.e.f. September 16, 2021.

\*\* Mr. Santanu Mukherjee was appointed as an Independent Director on the Board w.e.f. October 22, 2021.

# Mr. Yugandhar Meka resigned from the Board w.e.f. September 16, 2021.